Your browser is no longer supported. Please, upgrade your browser.
Settings
PRTK Paratek Pharmaceuticals, Inc. daily Stock Chart
PRTK [NASD]
Paratek Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.83 Insider Own3.90% Shs Outstand32.29M Perf Week-11.22%
Market Cap117.54M Forward P/E- EPS next Y-2.78 Insider Trans-5.28% Shs Float32.22M Perf Month17.42%
Income-124.20M PEG- EPS next Q-0.81 Inst Own69.50% Short Float25.63% Perf Quarter5.20%
Sales24.60M P/S4.78 EPS this Y-7.40% Inst Trans-3.10% Short Ratio6.77 Perf Half Y9.64%
Book/sh-1.25 P/B- EPS next Y30.80% ROA-45.10% Target Price15.50 Perf Year-44.09%
Cash/sh6.99 P/C0.52 EPS next 5Y- ROE- 52W Range2.66 - 7.39 Perf YTD-9.68%
Dividend- P/FCF- EPS past 5Y54.60% ROI-37.80% 52W High-50.74% Beta1.82
Dividend %- Quick Ratio9.40 Sales past 5Y104.60% Gross Margin93.00% 52W Low36.84% ATR0.28
Employees101 Current Ratio9.80 Sales Q/Q7768.00% Oper. Margin- RSI (14)45.94 Volatility8.36% 7.49%
OptionableYes Debt/Eq- EPS Q/Q1.00% Profit Margin- Rel Volume0.86 Prev Close3.80
ShortableYes LT Debt/Eq- EarningsFeb 11 AMC Payout- Avg Volume1.22M Price3.64
Recom1.70 SMA20-9.26% SMA501.57% SMA200-10.09% Volume1,042,593 Change-4.21%
Jan-08-20Initiated WBB Securities Speculative Buy $6
Jan-02-19Initiated Canaccord Genuity Buy $14
Nov-23-18Reiterated H.C. Wainwright Buy $55 → $22
Aug-27-18Initiated BofA/Merrill Neutral $13
Mar-02-18Downgrade Raymond James Strong Buy → Outperform
Oct-24-17Initiated Guggenheim Buy $44
Jul-18-17Reiterated H.C. Wainwright Buy $36 → $43
May-19-17Initiated Raymond James Strong Buy
Apr-11-17Reiterated H.C. Wainwright Buy $33 → $36
Apr-04-17Reiterated Wedbush Outperform $30 → $34
Apr-04-17Initiated Wedbush Outperform $30
Oct-27-16Resumed Leerink Partners Outperform $23
Jun-17-16Reiterated H.C. Wainwright Buy $31 → $34
May-13-16Initiated Robert W. Baird Outperform $30
Mar-30-16Resumed Cantor Fitzgerald Buy $27
Feb-29-16Initiated H.C. Wainwright Buy $32
Jul-22-15Initiated Gabelli & Co Buy $34
May-15-15Initiated Leerink Partners Outperform
May-12-15Initiated Cantor Fitzgerald Buy $35
May-11-15Initiated Guggenheim Buy $38
Jan-14-20 03:12PM  Find Cheap Highly-Ranked Stocks Trading Under $10 for 2020 Zacks -5.33%
Dec-20-19 08:38AM  Are Options Traders Betting on a Big Move in Paratek Pharmaceuticals (PRTK) Stock? Zacks
Dec-19-19 09:33PM  Why this King of Prussia biopharma's stock rose 32% Thursday American City Business Journals +32.20%
08:53AM  Paratek's stock rockets on government contract MarketWatch
07:52AM  The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic Benzinga
Dec-18-19 05:12PM  Paratek Awarded BARDA Project BioShield Contract for NUZYRA® GlobeNewswire
Dec-13-19 03:06PM  Is Paratek Pharmaceuticals Inc (PRTK) Going to Burn These Hedge Funds? Insider Monkey +5.48%
Dec-10-19 12:22PM  Seth Klarman Pares Paratek Pharmaceuticals Stake GuruFocus.com
Dec-06-19 08:00AM  12 Biotech Stocks Primed For A Short Squeeze Benzinga
Dec-02-19 04:05PM  Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Nov-30-19 11:02AM  Penny Stocks to Buy Using Technical Analysis for December 2019 Investopedia
Nov-28-19 06:59PM  Edited Transcript of PRTK earnings conference call or presentation 12-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-13-19 12:14PM  Did Changing Sentiment Drive Paratek Pharmaceuticals's (NASDAQ:PRTK) Share Price Down A Painful 79%? Simply Wall St. -8.19%
Nov-12-19 05:15PM  Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:05PM  Paratek Pharmaceuticals Generates Net Revenues of $3.9 Million in the Third Quarter of 2019 GlobeNewswire
Nov-05-19 10:31AM  Analysts Estimate Paratek Pharmaceuticals (PRTK) to Report a Decline in Earnings: What to Look Out for Zacks +24.53%
Nov-04-19 04:05PM  Paratek Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 12, 2019 GlobeNewswire
Nov-01-19 04:05PM  Paratek Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
07:38AM  The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance Benzinga
Oct-31-19 04:05PM  Paratek Announces Top Line Results of Phase 2 Clinical Studies of Omadacycline in Urinary Tract Infections GlobeNewswire
Oct-29-19 10:32AM  Earnings Preview: Paratek Pharmaceuticals (PRTK) Q3 Earnings Expected to Decline Zacks
Oct-18-19 07:07AM  The Daily Biotech Pulse: Intuitive Surgical Earnings, Paratek Pulls Out European Application For Antibiotic, Amgen's Evenity In Europe Benzinga -6.36%
Oct-17-19 04:05PM  Paratek Withdraws European Marketing Authorization Application for Oral and Intravenous NUZYRA in Skin Infections and Pneumonia GlobeNewswire
Oct-01-19 04:30PM  Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
10:07AM  Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019 PR Newswire
Sep-25-19 08:00AM  Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) Development Program at IDWeek 2019 GlobeNewswire
Sep-24-19 08:50AM  Paratek Pharmaceuticals (PRTK) Catches Eye: Stock Jumps 10.2% Zacks
Sep-23-19 01:16PM  Seth Klarman Further Increases Translate Bio Stake GuruFocus.com +10.22%
Sep-10-19 01:58PM  Baupost's Seth Klarman Dives Further Into Translate Bio GuruFocus.com +9.57%
12:33PM  Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): What Does Its Beta Value Mean For Your Portfolio? Simply Wall St.
Sep-09-19 08:00AM  Paratek Mourns Passing of Co-founder Dr. Stuart Levy GlobeNewswire +18.25%
Sep-04-19 08:00AM  Paratek Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference GlobeNewswire
Sep-03-19 04:05PM  Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Aug-30-19 01:31PM  Seth Klarman's Small Biotech Holdings GuruFocus.com +10.32%
08:00AM  The Lancet Infectious Diseases Publishes Results from Parateks Phase 3 Oral only Dosing Study of NUZYRA® (omadacycline) for Skin Infections GlobeNewswire
Aug-26-19 04:05PM  Paratek Pharmaceuticals to Present at Robert W. Bairds 2019 Global Healthcare Conference GlobeNewswire
Aug-13-19 02:07AM  Edited Transcript of PRTK earnings conference call or presentation 6-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-06-19 05:45PM  Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM  Paratek Pharmaceuticals Generates Net Revenues of $2.0 Million in the Second Quarter of 2019 GlobeNewswire
Aug-01-19 04:05PM  Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jul-29-19 04:05PM  Paratek Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 6, 2019 GlobeNewswire
Jul-25-19 10:33AM  Earnings Preview: Paratek Pharmaceuticals (PRTK) Q2 Earnings Expected to Decline Zacks
Jul-17-19 04:02PM  Melinta (MLNT) Announces Preliminary Product Sales for Q2 Zacks -6.93%
Jul-10-19 07:00AM  What Type Of Shareholder Owns Paratek Pharmaceuticals, Inc.'s (NASDAQ:PRTK)? Simply Wall St.
Jul-05-19 03:59PM  Heres What Hedge Funds Think About Paratek Pharmaceuticals Inc (PRTK) Insider Monkey
Jul-01-19 09:13AM  X-Biotix Therapeutics Joins Antimicrobials Working Group PR Newswire
Jun-25-19 04:01PM  Paratek Pharmaceuticals Promotes Evan Loh, M.D. to Chief Executive Officer; Michael Bigham to Assume Role of Executive Chairman GlobeNewswire
Jun-20-19 11:48AM  Biotech companies dominate fastest-growing public companies list again American City Business Journals
11:13AM  Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019 PR Newswire
Jun-07-19 09:27AM  Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections PR Newswire
May-20-19 07:15AM  Edited Transcript of PRTK earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents -6.81%
May-08-19 05:25PM  Paratek Pharmaceuticals (PRTK) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:25PM  Paratek: 1Q Earnings Snapshot Associated Press
04:05PM  Parateks NUZYRA (omadacycline) Generates Net Sales of $1.3 Million in the First Eight Weeks on the U.S. Market GlobeNewswire
May-01-19 10:32AM  Analysts Estimate Paratek Pharmaceuticals (PRTK) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-30-19 04:05PM  Paratek Pharmaceuticals to Report First Quarter 2019 Financial Results on May 8, 2019 GlobeNewswire
Apr-20-19 09:27AM  Should You Be Pleased About The CEO Pay At Paratek Pharmaceuticals, Inc.'s (NASDAQ:PRTK) Simply Wall St.
Apr-15-19 04:30PM  Paratek Pharmaceuticals Broadens Clinical Profile of NUZYRA (Omadacycline) with New ECCMID 2019 Data Presentations GlobeNewswire -6.33%
Apr-12-19 10:08AM  Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) PR Newswire
Apr-04-19 08:30AM  Paratek Pharmaceuticals Presenting New Data from NUZYRA (Omadacycline) Development Program at ECCMID 2019 GlobeNewswire
Apr-01-19 09:05AM  Paratek Pharmaceuticals Receives American Chemical Society 2019 Heroes of Chemistry Award GlobeNewswire +5.41%
08:10AM  Market Trends Toward New Normal in Verizon Communications, Digital Turbine, Vericel, Capstead Mortgage, Paratek Pharmaceuticals, and CryoPort Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Mar-28-19 08:00AM  Paratek Pharmaceuticals to Present at the 2019 H.C Wainwright Global Life Sciences Conference GlobeNewswire
Mar-20-19 01:35PM  Seth Klarman's Small Caps: Worth a Look? GuruFocus.com
Mar-18-19 08:00AM  Paratek Pharmaceuticals Announces Management Change GlobeNewswire
Mar-07-19 12:47PM  What Should Investors Know About Paratek Pharmaceuticals, Inc.s (NASDAQ:PRTK) Future? Simply Wall St.
Mar-05-19 07:49PM  Edited Transcript of PRTK earnings conference call or presentation 27-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-01-19 04:30PM  Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
08:00AM  Paratek Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference GlobeNewswire
Feb-27-19 09:08PM  Paratek Pharmaceuticals Inc (PRTK) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:01PM  Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Feb-20-19 10:31AM  Will Paratek Pharmaceuticals (PRTK) Report Negative Earnings Next Week? What You Should Know Zacks
Feb-14-19 04:05PM  Paratek Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-13-19 04:05PM  Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results on February 27, 2019 GlobeNewswire
Feb-06-19 05:05PM  New England Journal of Medicine Publishes Results from Pivotal Phase 3 Studies of Parateks NUZYRA (Omadacycline) For Pneumonia and Skin Infections GlobeNewswire
08:23AM  The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering Benzinga
Feb-05-19 04:05PM  Paratek Pharmaceuticals Launches NUZYRA (Omadacycline) in the United States GlobeNewswire
Feb-01-19 04:01PM  Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jan-18-19 11:09AM  What You Must Know About Paratek Pharmaceuticals, Inc.s (NASDAQ:PRTK) Beta Value Simply Wall St.
Jan-17-19 10:00AM  Antimicrobials Working Group Announces Updates to Leadership Team PR Newswire
Jan-02-19 04:01PM  Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire +8.58%
Dec-16-18 02:47AM  Arbiter Partners Capital Managements Returns, AUM and Holdings Insider Monkey
Dec-08-18 09:58PM  Hedge Funds Are Selling Paratek Pharmaceuticals Inc (PRTK) Insider Monkey
Dec-06-18 07:30AM  Analysis: Positioning to Benefit within Paratek Pharmaceuticals, Chesapeake Utilities, Eros International, Sunoco LP, Delek Logistics Partners, and Johnson Controls International plc Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Dec-03-18 04:01PM  Paratek Pharmaceuticals Files Two Patent Term Extensions in the United States; Expects NUZYRA Patent Protection Exclusivity Until at Least October 2030 GlobeNewswire
Nov-27-18 08:00AM  Paratek Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of Omadacycline in Acute Pyelonephritis, a Common Subset of Complicated Urinary Tract Infections GlobeNewswire
Nov-18-18 11:31PM  Edited Transcript of PRTK earnings conference call or presentation 6-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Nov-15-18 12:28PM  Do Institutions Own Paratek Pharmaceuticals Inc (NASDAQ:PRTK) Shares? Simply Wall St.
Nov-06-18 05:50PM  Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:48PM  Paratek: 3Q Earnings Snapshot Associated Press
04:02PM  Paratek Pharmaceuticals Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-01-18 04:05PM  Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Oct-26-18 04:05PM  Paratek Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 6, 2018 GlobeNewswire
08:45AM  Investor Expectations to Drive Momentum within Paratek Pharmaceuticals, Dell Technologies, Dover, Black Hills, Kinder Morgan, and Novo Nordisk A/S Discovering Underlying Factors of Influence GlobeNewswire
Oct-25-18 01:12PM  War against the superbugs: Mass. biotechs step up to fight antibiotic resistance American City Business Journals
Oct-22-18 01:56PM  5 Low-Priced Biotech Stocks to Take Advantage of the Market Rout InvestorPlace
Oct-05-18 10:55AM  Major Action in Biotech and This is The Next Winner ACCESSWIRE
Oct-04-18 04:30PM  Why Barnes & Noble, Paratek Pharmaceuticals, and Hortonworks Jumped Today Motley Fool +12.85%
04:01PM  Paratek Announces Acceptance of European Marketing Authorization Application for Oral and Intravenous Omadacycline GlobeNewswire
08:40AM  Paratek Pharmaceuticals (PRTK) in Focus: Stock Moves 8.7% Higher Zacks
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Haskel William M.Sr. VP, Sec. & General CounselDec 12Sale3.102,8648,878158,356Dec 16 06:11 PM
Brenner Randall B.Chief Development & RegulatoryDec 12Sale3.106,27819,46292,011Dec 16 06:08 PM
Loh EvanCEODec 12Sale3.1014,51444,993417,603Dec 16 06:06 PM
Woodrow AdamPresident & Chief CommercialDec 12Sale3.104,40113,643207,971Dec 16 06:03 PM
Woodrow AdamPresident & Chief CommercialOct 08Sale3.825,32220,330212,372Oct 08 08:58 PM
Loh EvanCEOOct 08Sale3.827,81829,865432,117Oct 08 08:55 PM
Brenner Randall B.Chief Development & RegulatoryOct 08Sale3.825,04919,28798,289Oct 08 08:45 PM
Loh EvanCEOOct 03Sale3.9816,26564,735413,935Oct 07 05:13 PM
Brenner Randall B.Chief Development & RegulatoryOct 03Sale3.987,67430,54391,338Oct 07 05:10 PM
Dietz Thomas JohnDirectorFeb 15Sale7.143,00021,4204,500Feb 20 04:57 PM
Radie Robert SDirectorFeb 15Sale7.143,75026,7756,750Feb 20 04:52 PM
Stein JeffreyDirectorFeb 15Sale7.143,37524,09810,125Feb 20 04:45 PM
Woodrow AdamVP & Chief Commercial OfficerFeb 05Sale6.773,33122,551144,694Feb 07 04:49 PM
Pagan Douglas W.Chief Financial OfficerFeb 05Sale6.772,49516,891134,057Feb 07 04:44 PM
Haskel William M.Sr. VP, Sec. & General CounselFeb 05Sale6.771,3319,011112,220Feb 07 04:38 PM